Body composition radiomics is an innovative field that leverages quantitative imaging features to provide precise, individualized health risk assessments. By applying advanced computational analysis to medical images, radiomics offers clinicians detailed insights into the distribution and quality of adipose tissue, muscle, and other body compartments. This review explores the epidemiology, pathophysiology, and clinical utility of body composition radiomics, emphasizing its role in risk stratification and personalized medicine. The discussion integrates contemporary research, clinical implications, guideline recommendations, and future directions for integrating radiomics into routine practice.
Advancements in imaging modalities such as CT, MRI, and PET have enabled a deeper understanding of body composition, moving beyond basic anthropometric indices. Radiomics, the high-throughput extraction of quantitative features from medical images, is emerging as a powerful tool to analyze body composition with unprecedented granularity. This approach holds promise for individualized risk prediction across a spectrum of diseases, particularly cardiovascular, metabolic, oncologic, and musculoskeletal conditions. For clinicians, the integration of radiomics into clinical workflows offers opportunities for more tailored prevention, risk assessment, and management strategies.
Obesity, sarcopenia, and altered body fat distribution are global health concerns, contributing to increased morbidity and mortality from cardiovascular disease, diabetes, cancer, and frailty. Epidemiological studies indicate that traditional metrics such as BMI fail to capture the complexity of body composition and its prognostic significance. Imaging-based assessments have demonstrated that visceral adiposity and ectopic fat deposition are more predictive of adverse outcomes than BMI alone. The burden of diseases linked to abnormal body composition underscores the need for precise phenotyping, which radiomics can facilitate on a large scale through automated, reproducible algorithms.
Body composition abnormalities such as visceral obesity, myosteatosis, and sarcopenia arise from complex pathophysiological mechanisms involving genetic, metabolic, and inflammatory pathways. Visceral adipose tissue is metabolically active, secreting adipokines and pro-inflammatory cytokines that promote insulin resistance, atherogenesis, and tumorigenesis. Conversely, loss of skeletal muscle mass and quality impairs glucose metabolism, physical function, and immune competence. Radiomics enables quantification of tissue heterogeneity and texture, revealing subtle changes in muscle and fat compartments that may reflect underlying cellular and molecular processes, thus improving the mechanistic understanding of disease progression.
Genetic predisposition, lifestyle factors (diet, physical activity), chronic diseases, aging, and medication use influence body composition. Radiomics enhances risk stratification by identifying imaging biomarkers associated with increased risk, such as high visceral-to-subcutaneous fat ratio, low muscle density, and increased intramuscular fat infiltration. These features may be present even in individuals with normal BMI, highlighting the limitations of conventional risk models and the importance of advanced imaging analytics in identifying at-risk populations.
Patients with adverse body composition phenotypes often present with features such as central obesity, reduced muscle strength, fatigue, and decreased functional capacity. However, many at-risk individuals are asymptomatic until advanced disease manifests. Radiomics-derived metrics from routine imaging studies (e.g., abdominal CTs for other indications) can provide opportunistic screening for sarcopenia or visceral obesity, enabling early intervention. Quantitative radiomic signatures also correlate with clinical outcomes, including postoperative complications, chemotherapy toxicity, and survival in cancer patients.
Traditional body composition assessment relies on dual-energy X-ray absorptiometry, bioelectrical impedance, or manual analysis of CT/MRI images. Radiomics automates and refines this process by extracting high-dimensional features that capture tissue texture, shape, and distribution. Machine learning algorithms can analyze these features to classify phenotypes and predict outcomes with higher accuracy. For example, radiomic analysis of L3 vertebral level CT images can provide rapid assessment of muscle mass and fat quality, which are strong predictors of morbidity and mortality in various clinical populations.
Personalized approaches to managing abnormal body composition include lifestyle modification, nutritional support, physical rehabilitation, and pharmacologic therapies. Radiomics-guided risk prediction allows for tailoring interventions to those most likely to benefit, optimizing resource allocation and improving outcomes. For instance, cancer patients identified as sarcopenic via radiomics may benefit from prehabilitation or intensified nutritional support prior to surgery or chemotherapy. Similarly, cardiometabolic risk reduction strategies can be targeted to patients with high visceral fat burden identified through imaging.
Recent advances in artificial intelligence and machine learning have accelerated the development of radiomic models capable of predicting disease risk, treatment response, and survival. Multi-omics integration, combining radiomic data with genomics and metabolomics, is poised to further enhance personalized risk prediction. Emerging therapies targeting adipose tissue biology and muscle anabolism are being evaluated in clinical trials, with radiomic metrics serving as potential biomarkers for treatment efficacy and safety monitoring.
While formal guidelines for radiomics in body composition assessment are evolving, expert consensus supports its use as an adjunct to clinical evaluation in high-risk populations. Radiomics should be integrated into multidisciplinary care pathways, with standardized protocols for image acquisition, feature extraction, and interpretation. Ongoing research and validation studies are needed to define thresholds for intervention and to ensure reproducibility across platforms and patient populations. Professional societies recommend further investigation into the clinical utility of radiomics, particularly for risk stratification in oncology, cardiology, and geriatrics.
Body composition radiomics represents a paradigm shift in personalized health risk prediction, offering clinicians detailed, objective, and actionable information beyond conventional assessments. Its integration into clinical practice has the potential to enhance prevention, early detection, and targeted management of diseases associated with abnormal body composition. Continued research, standardization, and interdisciplinary collaboration are essential for realizing the full potential of radiomics in advancing precision medicine for diverse patient populations.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation